# Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

> clinical trial · VERIFIED · 2026-08-18

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Somatostatin Receptor Positive

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06427798

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.